PDCD1LG2 and neoplasm: Mice treated with a combination of anti-PD-L1 and anti-PD-L2 showed robust proliferation of both OVA-specific TSL and Teff cells as anticipated (Fig. 5b,c and Extended Data Fig. 7c), as well as partial suppression of tumour growth (Extended Data Fig. 7a).